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A 17-yr-old female received a liver transplant for type 
I glycogen storage disease. A year later, when she 
experienced variceal gastrointestinal hemorrhage, an 
angiogram revealed thrombosis of the portal vein with 
hepatopetal collateral channels. A distal splenorenal 
shunt was performed because of failure of sclerotherapy 
to control subsequent bleeding episodes and the fact 
that the liver function was normal. This patient contin-
ues to have normal hepatic function with a patent sple-
norenal shunt 4 yr after the shunting procedure. This 
case illustrates the feasibility of a distal splenorenal 
shunt to alleviate portal hypertension in cases of throm-
bosis of the portal vein following hepatic transplantation 
if the liver function is normal. 
INTRODUCTION 
Survival rates and rehabilitation after orthotopic liver 
transplantation (OLT) have greatly improved during 
the so-called cyclosporine era (1). Nevertheless, tech-
nical problems are still significant (2) and reoperation 
is often required. Thrombosis of the hepatic artery and 
problems associated with biliary tract reconstruction 
represent the most important technical complications, 
with an incidence of7% and 13.2%, respectively (3,4). 
Thrombosis of the portal vein after OLT (reported 
incidence, 1.8%) has been observed almost exclusively 
in children (5). The diagnosis usually results from the 
development of clinical signs of portal hypertension, 
such as variceal hemorrhage, splenomegaly, and hyper-
splenism. The treatment is aimed at relieving the pre-
senting symptoms or correcting the underlying cause. 
In our experience, the therapy for posttransplantation 
portal vein thrombosis depends on the clinical presen-
tation, residual portal flow, and liver function. Conse-
quently, the therapeutic choices are sclerotherapy or 
retransplantation. 
We report herein a very unusual case of late portal 
thrombosis following OLT in a child. As a sequel to 
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this, the patient developed portal-portal hepatopetal 
collaterals sufficient to maintain good liver perfusion 
but unable to decompress the portal hypertension. She 
was successfully treated with a splenorenal shunt. 
CASE REPORT 
A 17-yr-old white female with end-stage liver disease 
secondary to type 1 glycogen storage disease was re-
ferred in January 1982 to our institution for OLT 
evaluation. Nine years before the referral, she under-
went end-to-side portacaval shunt to improve her 
growth and the metabolic abnormalities associated with 
glycogen storage disease (6). This treatment was effec-
tive in improving some aspects of her disease, such as 
lipid and uric acid metabolism, acidosis, and growth 
retardation. However, surgery did not relieve the fre-
quency of hypoglycemia, and appeared to have wors-
ened the clinical effect of the hypoglycemic episodes 
(7). Frequent daytime feeds and nighttime nasogastric 
feedings were necessary after the portacaval shunt to 
avoid symptomatic hypoglycemia. 
During this period, the child was followed with serial 
ultrasound examinations of the liver which began to 
reveal intrahepatic masses. A biopsy of one of these 
lesions proved to be an adenoma. 
In September 1981, the patient experienced the onset 
of severe abdominal pain and liver swelling which was 
thought to be related to a hemorrhage into the largest 
of the adenomas which led to biliary obstruction and 
hepatic failure. The child had an alkaline phosphatase 
of 3000 IU /L, ammonia of 315 j.Lg/L, and increased 
liver enzyme levels. Two months later, her condition 
deteriorated further, and she became jaundiced. The 
patient improved on total parenteral nutrition alone, 
and she returned to her base-line state of health. The 
decision was made to make the patient a liver transplant 
candidate, based on the fact that she had hepatic ade-
nomas with the potential risk of developing carcino-
matous changes or liver failure or both. 
Liver transplantation was performed using the tech-
nique previously described (8, 9). Immunosuppression 
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consisted of cyclosporine and prednisone ( I). Her initial 
postoperative course was complicated by a bile leak 
which was treated with drainage and sealed sponta-
neously. Nevertheless, liver function remained excellent 
and her subsequent clinical course was uneventful. 
One year after OLT, the patient was evaluated for 
gastrointestinal tract bleeding. Endoscopy showed 
esophageal and gastric varices. Angiography demon-
strated portal vein thrombosis and hepatopetal collat-
eral formation (Fig. I). Liver enzyme levels were nor-
mal. Treatment consisted of blood transfusions and 
endoscopic sclerosis of the varices. Despite this, she had 
several episodes of significant upper gastrointestinal 
tract bleeding over the next 3 months. Liver biopsy was 
normal, as were liver enzyme levels. 
Because of repeated episodes of gastrointestinal tract 
bleeding and the subsequent need for multiple trans-
fusions, a distal splenorenal shunt for control of portal 
hypertension was performed in June 1983. The anas-
tomosis measured approximately 13 mm in diameter. 
The splenorenal shunt decompressed the varices and 
resolved the gastrointestinal tract bleeding. 
Follow-up angiography performed in May 1984 (Fig. 
2), ultrasound performed in December 1986, and, more 
recently, a nuclear magnetic resonance test demon-
strated a widely patent splenorenal shunt. Over the past 
4 yr, the patient has not had any significant gastroin-
testinal tract bleeding. The most recent liver enzyme 
levels, performed in March 1987, were normaL 
FIG. I . Hepatopetal venous collaterals after portal vein thrombo-
sis following liver transplantation. Occlusion of the extrahepatic 
portal vein (long slraighl arrow) at tbe junction of the splenic and 
superior mesenteric veins demonstrated on subtraction venous phase 
film of selective superior mesenteric arteriogram. There is reconsti-
tution of the intrahepatic portal vessels (shari siraighl arrow) via 
multiple tortuous and dilated collateral vessels (curved arrows) to the 
right of the superior mesenteric vein and in the hilar region . There is 
portal hypertension as evidenced by retrograde flow in the splenic 
vein and marked gastroesophageal varices. 
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FIG. 2. A widely patent splenorenal shunt (arrow) is demonstrated 
on splenic venogram performed I yr after surgery. This study was 
performed by passing a catheter retrogradely through the shunt into 
the splenic vein via the left renal vein. (Courtesy of Philip Stanley, 
M.D., Children's Hospital of Los Angeles, CA). 
DISCUSSION 
Thrombosis of the portal vein after OLT has been 
reported by Lerut et al. (5) in seven of 393 hepatic 
grafts. The contributing factors in five of the seven 
patients were size mismatch, recipient portal vein 
thrombosis, and recipient portal vein hypoplasia. In the 
patient reported herein, the pre-existing end-to-side 
portacaval shunt may have predisposed the portal vein 
to thrombose. 
Thrombosis of the portal anastomosis is usually fol-
lowed by the development of collateral circulation, as 
first described by Hahn et al. (10). Such collaterals 
develop secondary to the high pressure in the extrahe-
patic portal venous system and, essentially, are of two 
types: portal-portal or hepatopetal, and portal-systemic 
or hepatofugal (I 1). Although some authors do not 
believe that hepatopetal collaterais that develop after 
portal vein thrombosis could be of any importance in 
maintaining good hepatic perfusion (12, 13), others 
have demonstrated that such collateral circulation is 
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important in reestablishing portal flow to the liver (11, 
14). 
In nontransplant patients with extrahepatic portal 
vein obstruction, the normal sinusoidal pressure is con-
sidered to be fundamental in favoring a periportal 
collateral pathway around the obstructed vein to the 
liver parenchyma (15). The development of a hepato-
petal collateral circulation results from the presence of 
many small collateral veins around the extrahepatic 
portal vein and within the hepatoduodenal and hepa-
tocolic ligaments. These small vessels enlarge because 
of a high pressure gradient between the proximal throm-
bosed extrahepatic portal vein, and the intrahepatic 
portal vein and sinusoidal system. 
The development of he pat ope tal collaterals after por-
tal vein thrombosis is clearly understandable in a native 
liver, but is more difficult to explain in a liver allograft. 
Thus, because all potential portal collaterals are divided 
during harvesting of the liver, the only connection 
between the splanchnic circulation and the allograft 
liver is via the portal anastomosis. Apparently, collat-
erals develop between the recipient extrahepatic portal 
segment and the allograft liver hilum, thus becoming 
the anatomical pathway for a possible hepatopetal col-
lateral circulation. In our case, the blood flow through 
these new collaterals was sufficient to perfuse the allo-
graft liver with the necessary hepatotrophic portal fac-
tors for a normal hepatic physiology, but not sufficient 
to maintain normal portal pressure. Consequently, por-
tal hypertension developed and led to esophageal var-
ices and severe gastrointestinal tract bleeding. In this 
setting, the therapeutic choices are sclerotherapy, re-
transplantation, or portal diversion surgery. 
Sclerotherapy is a good method to use to control 
acute variceal bleeding, but it is not always effective in 
permanent control of gastroesophageal bleeding and in 
the treatment of gastric varices. In the latter condition, 
the persistent hypertension in the gastric veins repre-
sents a life-threatening situation, since bleeding from 
erosive gastritis is a leading cause of death in this 
condition (16). As demonstrated in our patient, re-
peated sclerotherapy was ineffective in achieving defin-
itive control of bleeding. 
Retransplantation is a therapeutic option practiced 
routinely at our institution, rescuing those patients 
whose primary grafts are failing for primary nonfunc-
tion, intractable rejection, or technical complications 
(17). In our case, retransplantation was not performed 
because graft function remained excellent and its his-
tologic architecture was nornlal. 
The final therapeutic option, portasystemic shunting, 
would hopefully eliminate the recurrent bleeding epi-
sodes. The use of a selective shunting procedure might 
allow control of bleeding while preserving the necessary 
high pressure in the intestinal venous system. To main-
tain collateral portal perfusion with hepatotrophic por-
tal factors (16, 18), the distal splenorenal shunt was 
physiologically the most ideal shunt for the purpose 
just outlined. Further, the alternative mesocaval shunt 
was not selected because potential complications with 
this particular portosystemic diversion could lead to 
thrombosis of the superior mesenteric vein and subse-
quent loss of the hepatic allograft. In the distal spleno-
renal shunt, the surgical dissection is away from the 
hepatic hilum, which minimizes the risk of jeopardizing 
a future second transplant if one is needed (19). The 
long-term patency of the shunt without any recurrence 
of bleeding, and the excellent quality of liver function 
5 yr posttransplantation and 4 years after portal shunt-
ing, clearly demonstrate the reliability of this therapeu-
tic choice. 
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